Literature DB >> 10440118

Experimental diabetic neuropathy: an update.

A A Sima1, K Sugimoto.   

Abstract

Diabetic neuropathy consists of several clinical syndromes affecting motor, sensory and autonomic nerves. Of these the most common is distal symmetric sensory polyneuropathy usually referred to as diabetic neuropathy. Animal studies, mainly in diabetic rodents, have contributed tremendously to our understanding of this disease. From these it is clear that the pathogenesis of diabetic neuropathy is multifactorial involving sequentially occurring and often closely interrelated metabolic aberrations. Major pathogenetic mechanisms include increased activity of the polyol pathway, abnormalities in vasoactive substances, non-enzymatic glycation, increased presence of free radicals, and perturbed neurotrophism. Traditionally the neuropathies accompanying Type I (insulin-dependent) and Type II (non-insulin-dependent) diabetes mellitus have been regarded as identical. Recent investigations have, however, clearly delineated distinct differences in the functional and structural expressions of the neuropathies in the two types of diabetes. Major future challenges are the identification of the differences in underlying pathogenetic mechanisms in the two types of neuropathy and in gaining a better understanding of the hierarchy of the multifactorial mechanisms underlying the disease. This will be important for designing meaningful therapies which to date have failed miserably in diabetic neuropathy.

Entities:  

Mesh:

Year:  1999        PMID: 10440118     DOI: 10.1007/s001250051227

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  41 in total

Review 1.  [Diabetic neuropathy].

Authors:  Monika Lechleitner; Heidemarie Abrahamian; Claudia Francesconi; Markus Kofler
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

2.  Degeneration of the Golgi and neuronal loss in dorsal root ganglia in diabetic BioBreeding/Worcester rats.

Authors:  H Kamiya; W Zhang; A A F Sima
Journal:  Diabetologia       Date:  2006-09-20       Impact factor: 10.122

3.  Intra-axonal recording from large sensory myelinated axons: demonstration of impaired membrane conductances in early experimental diabetes.

Authors:  Jasna Kriz; Ante L Padjen
Journal:  Diabetologia       Date:  2003-02-18       Impact factor: 10.122

4.  Chronic oral pelargonidin alleviates streptozotocin-induced diabetic neuropathic hyperalgesia in rat: involvement of oxidative stress.

Authors:  Mohammadali Mirshekar; Mehrdad Roghani; Mohsen Khalili; Tourandokht Baluchnejadmojarad; Saiedeh Arab Moazzen
Journal:  Iran Biomed J       Date:  2010 Jan-Apr

5.  [Diabetic neuropathy].

Authors:  Monika Lechleitner; Heidemarie Abrahamian; Mario Francesconi
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

6.  Motor unit number estimate as a predictor of motor dysfunction in an animal model of type 1 diabetes.

Authors:  Nizar Souayah; Joseph G Potian; Carmen C Garcia; Natalia Krivitskaya; Christine Boone; Vanessa H Routh; Joseph J McArdle
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

7.  Beneficial effects of treadmill training in experimental diabetic nerve regeneration.

Authors:  Tais Malysz; Jocemar Ilha; Patrícia Severo do Nascimento; Katia De Angelis; Beatriz D'Agord Schaan; Matilde Achaval
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

8.  Antinociceptive activities of lidocaine and the nav1.8 blocker a803467 in diabetic rats.

Authors:  Tufan Mert; Yasemin Gunes
Journal:  J Am Assoc Lab Anim Sci       Date:  2012       Impact factor: 1.232

9.  Advanced Diabetic Neuropathy: A Point of no Return?

Authors:  Petr Boucek
Journal:  Rev Diabet Stud       Date:  2006-11-10

10.  Dietary G-rutin suppresses glycation in tissue proteins of streptozotocin-induced diabetic rats.

Authors:  Takashi Nagasawa; Nobuaki Tabata; Yoshiaki Ito; Youichi Aiba; Naoyuki Nishizawa; David D Kitts
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.